Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Monocyclic oga inhibitor compounds

A compound and selected technology, applied in organic chemistry, drug combination, nervous system diseases, etc., can solve problems such as cell cycle arrest and glycogen mobilization defects

Inactive Publication Date: 2019-10-01
JANSSEN PHARMA NV
View PDF12 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Oga deletion has resulted in defects in glycogen mobilization in pups and it caused genomic instability-associated cell cycle arrest in MEFs derived from homozygous knockout embryos

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monocyclic oga inhibitor compounds
  • Monocyclic oga inhibitor compounds
  • Monocyclic oga inhibitor compounds

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0114] The present invention relates to a compound of formula (I), or a compound of formula (I'), and pharmaceutically acceptable addition salts and solvates thereof, for use as defined above. Compounds of formula (I) are inhibitors of O-GlcNAc hydrolase (OGA) and are useful for the prophylaxis or treatment of tauopathies, in particular tauopathies selected from the group consisting of: Alzheimer progressive supranuclear palsy, Down syndrome, frontotemporal dementia, frontotemporal dementia with parkinsonism-17, Pick's disease, corticobasal degeneration, and argyrophilic granular disease; or available For the prevention or treatment of neurodegenerative diseases associated with tauopathies, especially neurodegenerative diseases selected from amyotrophic lateral sclerosis or frontotemporal dementia caused by C9ORF72 mutations.

[0115] In a particular embodiment, the invention relates to compounds of formula (I') as defined above, and tautomeric and stereoisomeric forms th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compoundsand compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.

Description

technical field [0001] The present invention relates to O-GlcNAc hydrolase (OGA) inhibitor having the structure shown in formula (I) [0002] [0003] wherein these groups are as defined in the specification. The present invention also relates to pharmaceutical compositions comprising such compounds, to processes for the preparation of such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, Such disorders are for example tauopathies, especially Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by tauopathies, especially amyotrophic lateral sclerosis or frontal sclerosis caused by C9ORF72 mutations temporal lobe dementia. Background technique [0004] O-GlcNAcylation is a reversible modification of proteins in which N-acetyl-D-glucosamine residues are transferred to the hydroxyl groups of serine and threonine r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D417/12C07D417/14C07D403/14
CPCC07D403/14C07D417/12C07D417/14A61P25/00A61P25/16A61P25/28A61P43/00C07D401/14C07D405/14C07D413/14C07D417/06
Inventor J.M.巴托洛梅-内布瑞达A.A.特拉班科-苏阿瑞兹M.J.阿尔卡扎-瓦卡C.M.马蒂内维图洛G.J.特瑞萨登张炜陈钢
Owner JANSSEN PHARMA NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com